Anti-Microbial Savior BioteQ Co., Ltd. (6864.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan · ISIN TW0006864002

Price
37.20 TWD
Market cap
1.40 bn TWD
P/E (2025)
–
P/S (2025)
1,987.99
Dividend yield
0.00 %
Net margin
-13,257.37 %
Return on equity (ROE)
-18.33 %
Return on assets (ROA)
-17.99 %

Anti-Microbial Savior BioteQ Co., Ltd. financials

Fiscal year20242025
Revenue612,000.00 TWD706,000.00 TWD
Gross profit144,000.00 TWD326,000.00 TWD
Operating income-76.48 m TWD-95.99 m TWD
EBIT-74.49 m TWD-93.58 m TWD
Net income-74.52 m TWD-93.60 m TWD
Diluted EPS – continuing operations-2.27 TWD-2.48 TWD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Anti-Microbial Savior BioteQ Co., Ltd.

Anti-Microbial Savior BioteQ Co., Ltd. focuses on the research and development of pharmaceutical drug products in Taiwan. The company offers PoroVance precision pore engineering and small-molecule drug discovery. Its pipeline products include FORMOSA-1117, antibacterial drug candidate; YUAN-03, antiviral drug candidate; AMS-2140, broad-spectrum antiviral drug candidate; TenTacle, ADC linker-conjugate compound. Anti-Microbial Savior BioteQ Co., Ltd. was founded in 2018 and is headquartered in Kaohsiung, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.